GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » CS Medica AS (XSAT:CSMED) » Definitions » Debt-to-EBITDA

CS Medica AS (XSAT:CSMED) Debt-to-EBITDA : -1.64 (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is CS Medica AS Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

CS Medica AS's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was kr2.15 Mil. CS Medica AS's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was kr9.11 Mil. CS Medica AS's annualized EBITDA for the quarter that ended in Mar. 2024 was kr-6.86 Mil. CS Medica AS's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 was -1.64.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for CS Medica AS's Debt-to-EBITDA or its related term are showing as below:

XSAT:CSMED' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.82   Med: 1.44   Max: 18.56
Current: -0.82

During the past 5 years, the highest Debt-to-EBITDA Ratio of CS Medica AS was 18.56. The lowest was -0.82. And the median was 1.44.

XSAT:CSMED's Debt-to-EBITDA is ranked worse than
100% of 425 companies
in the Medical Devices & Instruments industry
Industry Median: 1.26 vs XSAT:CSMED: -0.82

CS Medica AS Debt-to-EBITDA Historical Data

The historical data trend for CS Medica AS's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CS Medica AS Debt-to-EBITDA Chart

CS Medica AS Annual Data
Trend Sep19 Sep20 Sep21 Sep22 Sep23
Debt-to-EBITDA
18.56 7.17 1.44 -0.09 -0.56

CS Medica AS Quarterly Data
Sep19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.30 -0.37 -0.53 -0.76 -1.64

Competitive Comparison of CS Medica AS's Debt-to-EBITDA

For the Medical Devices subindustry, CS Medica AS's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CS Medica AS's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, CS Medica AS's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where CS Medica AS's Debt-to-EBITDA falls into.



CS Medica AS Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

CS Medica AS's Debt-to-EBITDA for the fiscal year that ended in Sep. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.192 + 8.587) / -15.823
=-0.55

CS Medica AS's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(2.154 + 9.111) / -6.856
=-1.64

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2024) EBITDA data.


CS Medica AS  (XSAT:CSMED) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


CS Medica AS Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of CS Medica AS's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


CS Medica AS (XSAT:CSMED) Business Description

Traded in Other Exchanges
Address
Fruebjergvej 3, Copenhagen, DNK, 2100
CS Medica AS is engaged in developing, manufacturing, and commercializing over-the-counter medical device products containing cannabinoids currently focusing on cannabidiol for the treatment of psoriasis and arthritis.

CS Medica AS (XSAT:CSMED) Headlines

No Headlines